SEC Form 4 · accession 0001445064-15-000101
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Coleman N Lannum III
Officer — VP, Investor Relations
Period of report
Jun 4, 2015
Accepted (ET)
Jun 8, 2015 · 8:00 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jun 4, 2015 | P | 1,000 | $126.20 | A | 4,890 | D | |
| Ordinary Shares | Jun 4, 2015 | P | 300 | $127.11 | A | 5,190 | D | |
| Ordinary Shares | holding | — | — | — | 100 | I | By wife | |
| Ordinary Shares | holding | — | — | — | 30 | I | By son (M) | |
| Ordinary Shares | holding | — | — | — | 30 | I | By son (R) | |
| Ordinary Shares | holding | — | — | — | 30 | I | By son (S) | |
| Ordinary Shares | holding | — | — | — | 20 | I | By mother |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price represents a weighted average. The shares were purchased in multiple transactions at prices ranging from $125.66 to $126.55, inclusive. Mr. Lannum will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range.